Novel Therapies for Right Ventricular Failure

Area of Science:

• Cardiovascular Medicine
• Pulmonary Hypertension Research
• Translational Cardiology

Background:

• Right ventricular failure (RVF) is a significant complication of cardiac and pulmonary disorders with a poor prognosis.
• Current treatments for RVF are limited, with strategies effective for left ventricular failure showing less success.
• Understanding RVF mechanisms is crucial for developing targeted therapies.

Purpose of the Study:

• To review contemporary and novel therapies for right ventricular failure (RVF).
• To explore the potential of emerging heart failure treatments in managing RVF.
• To highlight the need for a deeper understanding of RVF pathophysiology.

Main Methods:

• Review of current literature on right ventricular failure treatments.
• Exploration of contemporary heart failure therapies (e.g., ARNI, SGLT2i, sGC stimulators).
• Examination of novel pharmacological and device-centered interventions in preclinical studies.

Main Results:

• Emerging therapies targeting metabolism, calcium homeostasis, oxidative stress, and inflammation show preclinical promise for RVF.
• Interest is growing in epigenetic modifications as potential therapeutic targets for RVF.
• Novel pharmacological and cell-based options are being developed, aligning with precision medicine.

Conclusions:

• Contemporary therapies, including angiotensin receptor and neprilysin inhibitors, SGLT2 inhibitors, and sGC stimulators, may benefit RVF, especially when co-existing with left heart failure.
• Preclinical studies indicate novel interventions targeting various cellular pathways hold promise for RVF treatment.
• Further research into RVF mechanisms is essential for advancing precision medicine approaches and developing effective therapies.